

Press release

Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea

- **This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates**
- **SEOM-GEICAM-SOLTI Clinical Guidelines for Early Breast Cancer recommends the use of the MAF Test in the 2025 update**
- **The MAF Test® is now available to oncologists and pathologists in South Korea and will benefit an estimated 34,000 new patients each year**

Barcelona / Seoul, May 21st, 2026 – HJ HyupJin, a Seoul-based South Korean healthcare and precision diagnostics company, and Inbiomotion, proprietors of MAF Test® for identifying high risk early-stage breast cancer patients, have signed an agreement to start offering the MAF Test® in South Korea.

The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The MAF Test® also identifies those patients whose prognosis would worsen if treated or are being treated with bisphosphonates.

Breast cancer is the most common form of cancer among women, with more than 2 million new cases diagnosed globally each year. Approximately 1 in 8 women will develop breast cancer in their lifetime and, of these, 15-20% will eventually develop metastases. In South Korea, more than 34,000 women are newly diagnosed with breast cancer each year.

Thanks to this agreement, the MAF Test® will now be available in South Korea and could increase the survival of 8 out of 10 of the approximately 34,000 breast cancer patients diagnosed each year.

Choon Duk Kim, Managing Director of HJ HyupJin, said, "We are very pleased to introduce the MAF Test® to the South Korean market in collaboration with inbiomotion. We believe the MAF Test® has the potential to provide meaningful clinical value by supporting personalized treatment strategies and improving patient management. With over 10 years of marketing experience in the breast cancer field, we believe the MAF Test will become an important addition to our breast cancer portfolio and further strengthen our commitment to precision oncology in South Korea."

Ralf van den Berg, Chief Operating Officer of Inbiomotion, commented, "This partnership with HJ HyupJin marks an exciting new chapter for Inbiomotion as we take our first step into the Asia-Pacific region. South Korea is the ideal entry point – it has one of the most sophisticated oncology landscapes in the world, and a healthcare system that embraces innovation in precision medicine. We are confident that HJ HyupJin's expertise and established networks will ensure that the MAF Test® reaches the oncologists and patients who need it most. This is the beginning of a broader commitment to bringing personalised breast cancer care to patients across the region."

This agreement follows Inbiomotion's distribution partnerships for Spain and Portugal with Palex Medical, The Scientific Group for Sub-Saharan Africa, Source BioScience for United Kingdom and Ireland, and SPA Farma for Italy.

The clinical utility of MAF Test® is recognised in the 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, a key consensus document jointly developed by SEOM, GEICAM and SOLTI. The guidelines recommend the MAF Test® as a tool to help guide clinicians in identifying early-stage breast cancer patients who may benefit from adjuvant bisphosphonate treatment, and those for whom such treatment may not be appropriate.

About Inbiomotion

Inbiomotion is a spin-off of IRB Barcelona and ICREA, founded in 2011 by Dr. Roger Gomis, following the identification of the MAF gene as a biomarker to predict bone metastasis in breast cancer. Inbiomotion has developed a diagnostic kit based on the detection of MAF gene amplification, the MAF Test®, to promote precision medicine and improve the treatment of breast cancer patients. The company holds more than 200 patents and patent applications covering its proprietary MAF Test® FISH and the use of bisphosphonates in the adjuvant treatment of early-stage breast cancer patients. The company's main investors are Ysios Capital, Caixa Capital Risc, Alta Life Sciences and the Vila Casas Foundation. For more information, please visit www.inbiomotion.com.

About HJ HyupJin

HJ HyupJin is a South Korea-based healthcare and precision diagnostics company focused on bringing innovative molecular diagnostic technologies and advanced oncology solutions to the South Korean market. With expertise in regulatory strategy, clinical implementation, and hospital partnership development, HJ HyupJin is committed to accelerating the adoption of cutting-edge diagnostic technologies in Korea. The company works closely with healthcare providers, academic institutions, and industry partners to support evidence-based cancer care and personalized treatment decision-making.

About MAF Test®

MAF (mesenchymal aponeurotic fibrosarcoma gene, a transcription factor of the AP-1 family) is amplified in primary cancer tumours. It is associated with increased metastasis, especially bone metastasis. MAF transcriptionally controls genes such as PTHrP, which regulates metastasis-related cellular processes such as survival, initiation, metabolic rewiring and adhesion. The MAF Test® is a FISH (Fluorescence In Situ Hybridisation)-based diagnostic test that detects MAF gene amplification in tumour tissue from breast cancer patients at an early stage of the disease.

Contacts

Inbiomotion
Joël Jean-Mairet, PhD
Executive Chair
jjean-mairet@inbiomotion.com
+34 93 5173545

HJ HyupJin
Jim Lim
Business Development Director
jim.lim@hyupjincorp.com
+82 2 888 6030